Published in Hepatitis Weekly, May 24th, 1999
In this study, C. Vandelli and colleagues evaluated the efficacy of a 12-month course of recombinant interferon (alpha) (IFN-(alpha)2b) and assessed predictive factors of successful response to IFN therapy in chronic active hepatitis C (HCV CAH) ("Prediction of Successful Outcome in a Randomized Controlled Trial of the Long-Term Efficacy of Interferon (alpha) Treatment for Chronic Hepatitis C," Journal of Medical Virology, May 1999;58(1):26-34).
A total of 242 patients with histologically...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.